Weil is advising Abbott Laboratories, a global leader in diagnostics, medical devices, nutrition and branded generic pharmaceuticals, in its ~$21 billion acquisition of Exact Sciences, a leader in cancer screening and precision oncology diagnostics. The transaction is expected to close in the second quarter of 2026.

The Weil team is led by Antitrust partners Kristin Sanford, John Scribner and Michael Moiseyev, counsel Carla Hine, and associates Kathryn Graham, Megy Appalaraju, Danielle Norgren, Daniel Choi and Rahul Ramesh.